Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/7518
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlsagaff, Mochamad Yusuf-
dc.contributor.authorSusanti, Melly-
dc.contributor.authorThaha, Mochammad-
dc.contributor.authorJonatan, Christian-
dc.date.accessioned2024-11-07T07:07:51Z-
dc.date.available2024-11-07T07:07:51Z-
dc.date.issued2021-05-
dc.identifier.citationRiview Articleen_US
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/7518-
dc.description.abstractThe increasing rate of cardiovascular disorders contributes to rising hospitalized patients receive chronic oral beta-blocker therapy. Beta-blockers remain one of the fundamental therapy for chronic heart failure. Still, their role in decompensated heart failure and severe sepsis during hospitalization is often debated and inconsistent in clinical practice. In recent years, evidence of the efficacy and clinical outcomes of beta-blockers in acute heart failure (AHF) have accumulated. Clinical research indicates that chronic beta-blockade withdrawals should be prevented, or as soon as hemodynamic stabilization and euvolemic condition are reached, it should be reinstituted. As a subset of AHF patients with low cardiac output required inotropes, the choice of proper agent is fundamental. Different inotropic agents such as inhibitors of the phosphodiesterase, levosimendan, and dobutamine also their associations with beta-blockers are discussed.en_US
dc.language.isoen_USen_US
dc.publisherPharmacogn J.en_US
dc.subjectInotropesen_US
dc.subjectBeta-blockeren_US
dc.subjectDecompensated heart failureen_US
dc.subjectSevere sepsisen_US
dc.titleInotropes in Chronic Beta-Blocker Therapyen_US
dc.typeArticleen_US
Appears in Collections:VOL 13 NO 3 2021

Files in This Item:
File Description SizeFormat 
29.pdf402.4 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.